Sildenafil for congenital heart diseases induced pulmonary hypertension, a meta-analysis of randomized controlled trials
Open Access
- 20 July 2023
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 23 (1) , 1-12
Abstract
Background: Sildenafil was first prescribed for angina pectoris and then for erectile dysfunction from its effects on vascular smooth muscle relaxation and vasodilatation. Recently, sildenafil has been proposed for congenital heart diseases induced pulmonary hypertension, which constitutes a huge burden on children's health and can attribute to fatal complications due to presence of unoxygenated blood in the systemic circulation. Therefore, our meta-analysis aims to further investigate the safety and efficacy of sildenafil on children population. Methods: We searched the following electronic databases: PubMed, Cochrane CENTRAL, WOS, Embase, and Scopus from inception to April 20th, 2022. Randomized controlled trials that assess the efficacy of using sildenafil in comparison to a placebo or any other vasodilator drug were eligible for inclusion. The inverse variance method was used to pool study effect estimates using the random effect model. Effect sizes are provided in the form of mean difference (MD) with 95% confidence intervals (CI). Results: Our study included 14 studies with (n = 849 children) with a mean age of 7.9 months old. Sildenafil showed a statistically significant decrease over placebo in mean and systolic pulmonary artery pressure (PAP) with MD -7.42 (95%CI [-13.13, -1.71], P = 0.01) and -8.02 (95%CI [-11.16, -4.88], P < 0.0001), respectively. Sildenafil revealed a decrease in mean aortic pressure and pulmonary artery/aortic pressure ratio over placebo with MD -0.34 (95%CI [-2.42, 1.73], P = 0.75) and MD -0.10 (95%CI [-0.11, -0.09], P < 0.00001), respectively. Regarding post corrective operations parameters, sildenafil had a statistically significant lower mechanical ventilation time, intensive care unit stay, and hospital stay over placebo with MD -19.43 (95%CI [-31.04, -7.81], s = 0.001), MD -34.85 (95%CI [-50.84, -18.87], P < 0.00001), and MD -41.87 (95%CI [-79.41, -4.33], P = 0.03), respectively. Nevertheless, no difference in mortality rates between sildenafil and placebo with OR 0.25 (95%CI 0.05, 1.30], P = 0.10) or tadalafil with OR 1 (95%CI 0.06, 17.12], P = 1). Conclusion: Sildenafil is a well-tolerated treatment in congenital heart diseases induced pulmonary hypertension, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time, intensive care unit and hospital stay with no difference observed regarding mortality rates.Keywords
All Related Versions
Funding Information
- Ain Shams University
This publication has 34 references indexed in Scilit:
- Updated Clinical Classification of Pulmonary HypertensionJACC, 2013
- Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closureInteractive CardioVascular and Thoracic Surgery, 2013
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial HypertensionCirculation, 2012
- Pre‐operative sildenafil and pulmonary endothelial‐related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery*Anaesthesia, 2011
- Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non‐insulin‐dependent Otsuka Long‐Evans Tokushima Fatty ratsBritish Journal of Pharmacology, 2011
- Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart diseaseIntensive Care Medicine, 2010
- Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger???s SyndromeDrugs, 2008
- Sildenafil Prevents Rebound Pulmonary Hypertension after Withdrawal of Nitric Oxide in ChildrenAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Cardioprotection with phosphodiesterase-5 inhibition—a novel preconditioning strategyJournal of Molecular and Cellular Cardiology, 2004